{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(2)"],"submitter":["Kittipibul V"],"funding":["Merck Sharp & Dohme Corp","Merck Sharp and Dohme United Kingdom","Bayer AG","Bayer"],"pubmed_abstract":["<h4>Aims</h4>The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high-risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM-HF and DAPA-HF trials.<h4>Methods</h4>Subgroups of VICTORIA participants (n = 5050) were generated to simulate PARADIGM-HF and DAPA-HF trial populations. The PARADIGM-HF-eligible population excluded participants not meeting left ventricular ejection fraction (LVEF), estimated glomerular filtration rate (eGFR), and minimal dose criteria and those with high predicted probability of run-in failure. The DAPA-HF-eligible population excluded those n"],"journal":["ESC heart failure"],"pagination":["1479-1484"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11911596"],"repository":["biostudies-literature"],"pubmed_title":["Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial."],"pmcid":["PMC11911596"],"pubmed_authors":["McMullan C","O'Connor CM","Mentz RJ","Anstrom KJ","Ezekowitz JA","Kittipibul V","Voors A","VICTORIA Study Group","Young R","Corda S","Lam CSP","Butler J","Ponikowski P","Armstrong PW"],"additional_accession":[]},"is_claimable":false,"name":"Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.","description":"<h4>Aims</h4>The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high-risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM-HF and DAPA-HF trials.<h4>Methods</h4>Subgroups of VICTORIA participants (n = 5050) were generated to simulate PARADIGM-HF and DAPA-HF trial populations. The PARADIGM-HF-eligible population excluded participants not meeting left ventricular ejection fraction (LVEF), estimated glomerular filtration rate (eGFR), and minimal dose criteria and those with high predicted probability of run-in failure. The DAPA-HF-eligible population excluded those n","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T19:02:26.916Z","creation":"2025-04-04T03:02:15.615Z"},"accession":"S-EPMC11911596","cross_references":{"pubmed":["39434631"],"doi":["10.1002/ehf2.15134"]}}